Diabetes Care:1型糖尿病对肾脏的影响你知道么?

2017-09-26 MedSci MedSci原创

大多数人认为,只有少数1型糖尿病患者(T1D)会发展为晚期肾脏疾病,并且在男性患者中发病率较高,年龄较小的患者发生率较低。然而,直到最近发现,由于只有较少的T1D患者幸存到老年,因此,其长期风险尚不清楚。近期,一项发表在杂志Diabetes Care上的研究评估了在1950-1980年间(n = 932;平均基线年龄29岁,持续19年)诊断的儿童T1D队列中的50年累积肾脏并发症风险。受试者中有1

大多数人认为,只有少数1型糖尿病患者(T1D)会发展为晚期肾脏疾病,并且在男性患者中发病率较高,年龄较小的患者发生率较低。然而,直到最近发现,由于只有较少的T1D患者幸存到老年,因此,其长期风险尚不清楚。


近期,一项发表在杂志Diabetes Care上的研究评估了在1950-1980年间(n = 932;平均基线年龄29岁,持续19年)诊断儿童T1D队列中的50年累积肾脏并发症风险。受试者中有144人在基线前死亡,130人接受定期评估,658人进行两年度调查,最多的接受了为期25年的9次评估。微量和大量白蛋白尿定义为:白蛋白分泌率分别为20-199和≥200μg/ min,终末期肾病(ESRD)为透析或肾移植。在20至50岁之间评估10年间的累计发病率,并与糖尿病发病年数进行比较。

经过50年的T1D持续时间,ESRD影响了60%的研究队列;大量白蛋白尿72%;和微量白蛋白尿88%。除了ESRD(40年T1D持续时间里,微量白蛋白尿增加3%,大量白蛋白尿无变化;ESRD 下降45%),近期队列累积发病率下降的证据不足。6岁以前发病风险最低;发病率没有因性别而异。

此项研究表明:T1D中的一些肾脏疾病在长时间内几乎是普遍存在的,并且没有下降,这对保健和研究策略有重要的影响。ESRD发生了下降了,但为期40年的时间里,它们仍然继续影响> 25%的患者。

原始出处:
Costacou T, Orchard TJ. Cumulative Kidney Complication Risk by 50 Years of Type 1 Diabetes: The Effects of Sex, Age, and Calendar Year at Onset. Diabetes Care. 2017 Sep 20. pii: dc171118. doi: 10.2337/dc17-1118.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1760217, encodeId=b1c41e60217c0, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue May 08 03:28:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638051, encodeId=e32b163805108, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jan 05 01:28:00 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901781, encodeId=eb401901e81e2, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Jul 15 06:28:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247938, encodeId=7f3924e9383f, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Sep 26 19:10:37 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247930, encodeId=f81b24e93014, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue Sep 26 19:00:44 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1760217, encodeId=b1c41e60217c0, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue May 08 03:28:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638051, encodeId=e32b163805108, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jan 05 01:28:00 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901781, encodeId=eb401901e81e2, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Jul 15 06:28:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247938, encodeId=7f3924e9383f, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Sep 26 19:10:37 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247930, encodeId=f81b24e93014, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue Sep 26 19:00:44 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1760217, encodeId=b1c41e60217c0, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue May 08 03:28:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638051, encodeId=e32b163805108, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jan 05 01:28:00 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901781, encodeId=eb401901e81e2, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Jul 15 06:28:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247938, encodeId=7f3924e9383f, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Sep 26 19:10:37 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247930, encodeId=f81b24e93014, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue Sep 26 19:00:44 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1760217, encodeId=b1c41e60217c0, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue May 08 03:28:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638051, encodeId=e32b163805108, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jan 05 01:28:00 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901781, encodeId=eb401901e81e2, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Jul 15 06:28:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247938, encodeId=7f3924e9383f, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Sep 26 19:10:37 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247930, encodeId=f81b24e93014, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue Sep 26 19:00:44 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
    2017-09-26 131****1460

    学习了受益匪浅

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1760217, encodeId=b1c41e60217c0, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue May 08 03:28:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638051, encodeId=e32b163805108, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jan 05 01:28:00 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901781, encodeId=eb401901e81e2, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Jul 15 06:28:00 CST 2018, time=2018-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247938, encodeId=7f3924e9383f, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Sep 26 19:10:37 CST 2017, time=2017-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247930, encodeId=f81b24e93014, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue Sep 26 19:00:44 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
    2017-09-26 yfjms

    学习了

    0

相关资讯

JCEM:1型糖尿病中β细胞的定量研究

1型糖尿病患者中长期存在的β细胞功能似乎很大程度上是由于之前存留的β细胞,没有任何证据表明β细胞再生或小岛/导管组织再生或从其他胰岛内分泌细胞类型分化转移。

Lancet:连续血糖监测对患1型糖尿病的孕妇血糖控制及新生儿预后的影响。

患有1型糖尿病的孕妇属于高危人群,建议尽可能达到最佳血糖控制,但该孕妇人群的新生儿预后尚不理想。Denice S Feig及其同事对持续血糖监测(CGM)对母体血糖控制和产科及新生儿健康预后的影响进行研究。

Diabetes Care:识别青少年1型糖尿病的现状

近期,一项发表在杂志Diabetes Care上的研究旨在建立青少年糖尿病(PAID-T)规模的分界线,以确定具有临床意义和糖尿病高危险的青少年。此项研究的数据从糖尿病管理和长期赋权与成功影响(MILES)的澳大利亚青年研究中获得,此项研究是一项全国性调查,用于评估自主选择的国家糖尿病服务计划注册者中的各种心理社会指标。此项研究的参与者(n = 537)的平均(平均值±SD)年龄为16±2岁,患有

1型糖尿病口服药 潜力无限!

1型糖尿病起病比较急剧,必须用胰岛素治疗才能获得满意疗效,目前还没有治疗1型糖尿病的口服药。近日,在葡萄牙首都里斯本举行的第53届欧洲糖尿病研究协会年会上,科罗拉多大学Anschutz医学院公布了口服糖尿病药物——SGLT1/SGLT2双抑制剂的3期临床试验数据,为1型糖尿病患者减少胰岛素需求提供了可能。

PNAS:1型糖尿病的更佳疗法,向皮肤“移植”胰岛细胞

1型糖尿病,原名胰岛素依赖型糖尿病,多发生在儿童和青少年,也可发生于各种年龄。起病比较急剧,体内胰岛素绝对不足,容易发生酮症酸中毒,必须用胰岛素治疗才能获得满意疗效,否则将危及生命。来自多伦多大学生物材料和生物医学工程学院的研究人员通过研究发现,皮下的空间或许是治疗1型糖尿病的最佳位置。

Diabetic Med:探索为什么1型糖尿病年轻人拒绝结构化教育?

近日,国际杂志 《Diabetic Medicine》上在线发表一项关于探索为什么1型糖尿病年轻人拒绝结构化教育,确定影响年轻1型糖尿病(13-21岁)患者与结构化糖尿病教育(SDE)缺乏接触的因素,以告知和扩大未来SDE的范围。